Introduction
Mercaptopurine (MP) is a purine antimetabolite widely used in the treatment of acute lymphoblastic leukemia (ALL) 1 . MP is an inactive prodrug that requires intracellular activation catalyzed by multiple enzymes, to exert cytotoxicity (Supplemental Figure A) [2] [3] [4] [5] . MP is converted by hypoxanthine guanine phosphoribosyltransferase (HGPRT) into thioinosine monophosphate (TIMP) and subsequently into thioguanosine monophosphate (TGMP) by a two-step process involving inosine monophosphate dehydrogenase (IMPDH) and guanosine monophosphate synthetase (GMPS) 2 .
Subsequently, TGMP can be converted into the active thioguanine nucleotides (TGN) by adenosine kinase 2;6;7 . Cytotoxic effects of MP are achieved primarily through incorporation of TGN into RNA and DNA 8;9 . The incorporation of TGN, as deoxy-TGN triphosphate, inhibits the function of several enzymes involved in DNA replication and repair 10;11 and induces DNA damage such as single-strand breaks, DNA-protein crosslinks, interstrand cross-links and sister chromatid exchanges [12] [13] [14] [15] . The pathway leading to TGN synthesis is in competition with inactivation pathways catalyzed by xanthine oxidase (XDH) or thiopurine methyltransferase (TPMT) 16 .
Numerous clinical studies have reported substantial inter-patient variability in intracellular TGN concentrations during continuation therapy of acute lymphoblastic leukemia (ALL) 5;17-19 . Determinants of this variability include differences in MP absorption, genetic polymorphism of TPMT, and patient compliance to treatment [20] [21] [22] [23] .
Inter-patient differences in intracellular TGN concentrations have been associated with treatment outcome in children with ALL, whereas variability in MP plasma concentrations has not. Patients with TGN accumulation above the population average had a better
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In most treatment protocols for childhood ALL, MP is administered in combination with methotrexate (MTX). The pharmacological rationale for this combination is based in part on a direct effect of MTX on enzymes involved in TGN metabolism 25 or indirectly through its effect on plasma purines 17;26;27 . Recently, it has been shown that patients NC) was given orally. As previously described 28 , use of allopurinol at least 72 hours prior to bone marrow aspiration did not alter thiopurine metabolite levels among treatment groups. For TGN analysis, we divided patients into three groups according to the randomized treatment arms (MP, n=33; HDMTX+MP, n=29; LDMTX+MP, n=20).
Isolation of ALL blasts from bone marrow aspirate. For all 82 patients, ALL cells
at the time of diagnosis and 20 hours after initiation of the MP infusion (post-treatment)
were obtained and processed as previously described 33 . The percent of leukemic blasts in bone marrow aspirates at diagnosis and post-treatment was similar (median: 97% and 95%). The final cell yield was determined by hemocytometer and viability by trypan blue exclusion. scaled to the target intensity of 2500 and log-transformed. From the total of 12,599 probe sets, those expressed in less then 5 percent of the 82 patients were omitted, leaving 5,013 probe sets for subsequent analyses. Analyses were performed separately in the two groups of patients treated with either MP alone or with the combination of MTX plus MP. Spearman's rank correlation and false discovery rate (FDR) using Storey's q-value 42 were computed to identify genes associated with TGN concentration.
Leave-one-out cross-validation using support vector machine (SVM) based on Spearman's rank correlation was used to assess the validity of association between gene expression profiles and TGN concentrations. Table C However, there were only two TPMT heterozygotes and no TPMT deficient patients among the 60 patients genotyped.
Relation between gene expression and intracellular TGN accumulation.
Unsupervised hierarchical clustering, which groups patients based on predominant similarities in overall gene expression, did not cluster patients according to ALL TGN concentrations (Supplemental Figure C) . However, Spearman's rank correlation and leave-one-out cross-validation using support vector machine (SVM) identified 60 gene probe sets (rho=0.60, p<0.001, FDR=45%) (Supplemental Figure 3A) ; and the degree of discrimination between these two groups of patients is evident by PCA ( Figure 3B) . Figure D) . Figure M1) .
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Discussion
Intracellular accumulation of thioguanine nucleotides (TGN) is a critical event for the cytotoxic effects of mercaptopurine 8;9 . Previous studies have shown that several factors, including the activity of enzymes involved in MP metabolism, MP dose intensity, drug-drug interactions and patient compliance significantly influence inter-patient differences in TGN concentrations 18;44;45 . Furthermore, these inter-patient differences have been associated with treatment efficacy 3;5;24 and MP toxicity 23;46 .
Well defined sources of variability include inherited differences in TPMT 36;46-48 and inhibition of xanthine oxidase by allopurinol 49 . Consistent with previous reports from our lab and others 26;28 , the present study revealed a significant in vivo effect of MTX on intracellular accumulation of TGN, when compared to treatment with MP given alone (p<0.001). The current study also documented substantial inter-patient variability in TGN accumulation that is not explained by these drug interactions or by inherited differences in TPMT activity.
We evaluated MP with or without MTX as initial therapy, because that is the only time during which it would be possible to assess MP dispositions and effects in primary cells after in vivo treatment (i.e., by week 4 most patients have no ALL cells in their peripheral blood or bone marrow). In our study, we were focused on treatment naïve and NDUFS1), enzymes involved in purine metabolism (e.g., ADA and XDH), regulation of cell cycle (e,g., ANAPC5 and CCT4) and apoptosis (e.g., CASP7 and PRKR).
Interestingly, only two (XDH and ADA) of the genes identified in the current study have been previously associated with MP metabolism and disposition. Expression of SLC29A1 (or ENT1), a member of the family of the equilibrative nucleoside transporters which mediates uptake of nucleosides and chemotherapeutic agents 39;51 , has been shown to be positively associated with cytotoxicity of nucleoside analogues (e.g., MP, azacytidine, cytarabine and inosine-glycodialdehyde) in human cancer cell lines 52 and clinical response to cytarabine in patients with acute myeloid leukemia 53 . Consistent with this, in our patients, SLC29A1 expression was high in ALL cells that accumulated high post-treatment TGN concentrations (rho=0.54, p=0.0015).
We measured TGN accumulation in CEM, Nalm-6, MOLT-4 human leukemia cells after exposure to MP in the presence or absence of NBMPR, a specific inhibitor of Together, these in vivo and in vitro data provide new insights into the genomic basis of inter-patient differences in TGN accumulation in ALL cells, and reveal significant differences when MP is given alone or in combination with MTX.
